Albemarle's (ALB) "Buy" Rating Reiterated at Truist Financial

Key Points

• Truist reaffirmed its Buy rating on Albemarle but cut its price target to $170 from $185, implying 72.4% upside from the cited share price of $98.61.
• Analyst views are mixed: the consensus rating is Hold, with an average price target of $177.64; 15 analysts rate the stock Buy, seven Hold, and three Sell.
• Albemarle beat quarterly estimates, reporting EPS of $2.58 versus $2.53 expected and revenue of $1.55 billion, up 18.8% year over year.

Albemarle (NYSE:ALB - Get Free Report)'s stock had its "buy" rating reaffirmed by equities research analysts at Truist Financial in a report issued on Friday, Benzinga reports. They currently have a $170.00 target price on the specialty chemicals company's stock, down from their prior target price of $185.00. Truist Financial's target price indicates a potential upside of 72.40% from the stock's current price.

Several other research firms have also recently commented on ALB. JPMorgan Chase & Co. reduced their target price on shares of Albemarle from $160.00 to $140.00 and set a "neutral" rating for the company in a research note on Tuesday, August 25th. Royal Bank Of Canada dropped their price target on shares of Albemarle from $157.00 to $129.00 and set an "outperform" rating on the stock in a research note on Thursday, October 15th. Barclays cut their price target on shares of Albemarle from $109.00 to $95.00 and set an "equal weight" rating for the company in a report on Friday. Morgan Stanley restated a "reduce" rating and issued a $161.00 price objective on shares of Albemarle in a research report on Monday, August 10th. Finally, Citigroup lowered their price objective on Albemarle from $175.00 to $125.00 and set a "buy" rating on the stock in a report on Thursday, October 22nd. Fifteen investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $177.64.

Albemarle Stock Performance

Shares of Albemarle stock traded up $0.24 during trading hours on Friday, hitting $98.61. 1,084,834 shares of the company were exchanged, compared to its average volume of 2,469,517. Albemarle has a 1 year low of $89.77 and a 1 year high of $221.00. The company has a current ratio of 2.09, a quick ratio of 1.35 and a debt-to-equity ratio of 0.22. The business has a 50-day moving average of $108.33 and a 200-day moving average of $148.24. The stock has a market capitalization of $11.64 billion, a price-to-earnings ratio of 23.77, a P/E/G ratio of 0.57 and a beta of 1.34.

Albemarle (NYSE:ALB - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The specialty chemicals company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. Albemarle had a return on equity of 15.23% and a net margin of 10.40%. The firm had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.52 billion. During the same period last year, the company earned ($0.19) earnings per share. The company's revenue for the quarter was up 18.8% on a year-over-year basis. As a group, analysts expect that Albemarle will post 11.15 EPS for the current fiscal year.

Institutional Trading of Albemarle

Institutional investors have recently added to or reduced their stakes in the stock. Addison Advisors LLC acquired a new stake in shares of Albemarle during the 2nd quarter valued at approximately $28,000. Dakota Community Bank & Trust NA purchased a new stake in shares of Albemarle during the 1st quarter worth approximately $54,000. Fiduciary Financial Advisors acquired a new stake in shares of Albemarle in the 2nd quarter worth approximately $41,000. Valley National Advisers Inc. grew its holdings in shares of Albemarle by 3,700.0% in the 3rd quarter. Valley National Advisers Inc. now owns 304 shares of the specialty chemicals company's stock worth $32,000 after acquiring an additional 296 shares during the period. Finally, Jones Financial Companies Lllp acquired a new stake in shares of Albemarle in the 2nd quarter worth approximately $42,000. Hedge funds and other institutional investors own 92.87% of the company's stock.

More Albemarle News

Here are the key news stories impacting Albemarle this week:

• Positive Sentiment: Albemarle reported Q3 adjusted earnings of $2.58 per share and revenue of $1.55 billion, both above analyst estimates. Revenue rose 18.8% year over year, and the company swung to a profit from a loss a year earlier. Reports attributed the earnings improvement to higher lithium prices, which also supported stronger cash flow. Article: ALB Q3 Earnings Beat Estimates on Higher Lithium Pricing
• Positive Sentiment: Scotiabank maintained a Sector Outperform rating and a $190 price target, forecasting EPS of $11.64 for FY2026 and $14.15 for FY2027—above the cited $11.15 current-year consensus estimate. Those projections point to potential earnings growth, though they are analyst forecasts rather than company guidance.
• Negative Sentiment: Barclays lowered its price target to $95 from $109 and kept an Equal Weight rating, implying downside from the cited share price. The reduced target signals a more cautious view and may limit enthusiasm following the earnings report. Barclays ratings

About Albemarle

Albemarle Corporation NYSE: ALB is a global specialty chemicals company headquartered in Charlotte, North Carolina. The company develops, manufactures, and markets engineered chemicals used in energy storage, transportation, refining, pharmaceuticals, agriculture, consumer products, and other industrial applications.

Albemarle is one of the world's major producers of lithium and supplies lithium compounds, including lithium carbonate and lithium hydroxide, for use in rechargeable batteries for electric vehicles, portable electronics, and grid energy-storage systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.